Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tenon Medical, Inc. (NASDAQ: TNON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tenon is a medical device company focused on sacroiliac (SI) joint and sacro-pelvic fusion systems, including the Catamaran and SImmetry platforms. Its filings give investors detailed information on capital raising transactions, acquisitions, equity compensation, governance decisions and financial reporting related to this sacro-pelvic fusion business.
Recent Form 8‑K filings describe material events such as the November 10, 2025 securities purchase agreements for an at‑the‑market PIPE financing, in which Tenon agreed to issue common stock and common stock purchase warrants, generating approximately $2.85 million in gross proceeds for working capital and general corporate purposes. Another 8‑K filed on August 6, 2025 outlines the asset purchase agreements for the SiVantage (SImmetry business) and SIMPL Medical portfolios, including cash, equity, royalty and earnout components, along with related employment agreements for key executives joining Tenon.
Filings also cover equity and governance matters. An 8‑K dated October 16, 2025 reports the issuance of restricted stock units to Tenon’s directors and officers under the 2022 Equity Incentive Plan, with specified vesting schedules. An 8‑K filed September 23, 2025 details the results of the 2025 Annual Meeting of Stockholders, including election of directors, approval of warrant exercisability, amendments to the equity incentive plan and ratification of the independent auditor. An 8‑K/A filed October 17, 2025 provides financial statements of SiVantage and unaudited pro forma condensed combined financial information reflecting the acquisition.
Through Tenon’s periodic reports and accompanying exhibits, investors can review condensed balance sheets, statements of operations and comprehensive loss, and pro forma financials that show how acquisitions affect the company’s financial position. Stock Titan enhances this information with AI-powered summaries that explain key terms in plain language, highlight important elements of PIPE financings, asset purchase agreements and equity awards, and help users quickly identify items such as warrant terms, earnout structures and royalty obligations. The filings page also surfaces insider-related equity grants reported in 8‑Ks, giving a clearer view of how management and directors are compensated through stock and restricted stock units.
By combining real-time EDGAR updates with AI-generated insights, the Tenon Medical filings section helps users understand how capital structure changes, acquisitions of sacro-pelvic technologies and governance decisions relate to the company’s strategy in SI joint fusion and sacro-pelvic fixation.
Tenon Medical, Inc. director reports RSU vesting and share sale
A director of Tenon Medical, Inc. (TNON) reported equity transactions involving restricted stock units and common stock. On January 1, 2026, 10,732 restricted stock units converted into 10,732 shares of common stock, increasing the director’s holdings. On January 5, 2026, 3,327 shares of common stock were disposed of at a price of $0.9301 per share to satisfy tax liabilities related to the RSU vesting. Following these transactions, the director directly held 8,462 shares of common stock.
Tenon Medical, Inc. (TNON) CEO and President Steven Foster reported buying additional company stock in a private transaction. On November 14, 2025, he purchased 19,455 shares of common stock, increasing his direct holdings to 22,878 shares after the transaction. The purchase was part of a securities purchase agreement for a private investment in which each share of common stock was sold together with a warrant.
Along with the shares, Foster also acquired warrants to purchase up to 19,455 additional common shares. The combined purchase price for each share and accompanying warrant was $1.285, and the warrants have an exercise price of $1.16 per share and expire on November 14, 2028. These details show how a key executive has recently committed more capital to Tenon Medical through both stock and long-term warrants.
Tenon Medical's Chief Innovation Officer reported buying additional stock and warrants in the company. On November 14, 2025, the officer purchased 19,455 shares of common stock in an at-the-market private investment in public equity transaction at a combined price of $1.285 per share and accompanying warrant.
The officer also received warrants to purchase up to 19,455 shares of common stock at an exercise price of $1.16 per share, exercisable starting November 14, 2025 and expiring November 14, 2028. Following this transaction, the officer directly beneficially owned 157,569 shares and indirectly beneficially owned 350,765 shares through SiVantage, Inc.
Tenon Medical, Inc. (TNON) reported that its Chief Commercial Officer filed a Form 4 disclosing participation in an at-the-market private investment in public equity transaction. On November 14, 2025, the officer purchased 101,167 shares of common stock and received warrants to purchase up to 101,167 additional shares of common stock. The purchase price for each share and accompanying warrant unit was $1.285.
The warrants have an exercise price of $1.16 per share and are exercisable from November 14, 2025 until November 14, 2028. Following the transaction, the officer directly beneficially owned 239,281 shares of common stock and indirectly held 175,383 shares through SiVantage, Inc., reflecting a 24.69% equity interest in that entity.
Tenon Medical, Inc. entered into securities purchase agreements with accredited investors to sell 2,217,904 shares of common stock and accompanying warrants at a combined price of $1.285 per share and warrant. The warrants have an exercise price of $1.16 per share and a three-year term. The offering closed with the issuance of 2,217,904 shares and warrants to purchase 2,217,904 shares, providing approximately $2.85 million in gross proceeds that the company plans to use for working capital and general corporate purposes. Senior executives, including the CEO, CCO, and Chief Innovation Officer, participated as purchasers. The company must file a registration statement for the shares and warrant shares within 30 days, and the transaction was conducted as an unregistered private placement under Section 4(a)(2) and Regulation D.
Tenon Medical (TNON) reported Q3 results and completed two asset acquisitions to expand its SI joint portfolio. Revenue was $1.173 million versus $0.887 million a year ago, with gross margin improving to 66% from 47% as higher volumes reduced fixed production costs per unit. Net loss was $3.339 million compared with $3.184 million.
Cash and cash equivalents were $3.442 million as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern for one year after issuance, and plans to seek additional financing.
In August, Tenon acquired substantially all assets of SiVantage and SIMPL (treated as a single business combination) for total consideration of $3.127 million, including $0.75 million in cash, 710,300 shares, and contingent consideration; goodwill recorded was $2.407 million. As a subsequent event, the company announced a $2.85 million PIPE financing, issuing 2,217,904 common shares and warrants to purchase 2,217,904 shares at a combined price of $1.285 per share-and-warrant, with warrants exercisable at $1.16.
Shares outstanding were 8,605,740 as of November 13, 2025.
Tenon Medical, Inc. filed an Amendment No. 1 to Form 8-K to add required financial information related to its previously reported acquisition of substantially all assets of SiVantage, Inc. The amendment updates Item 9.01 to present the acquired business’s financial statements and the company’s unaudited pro forma financials.
Exhibit 99.1 includes SiVantage’s audited financial statements for the year ended December 31, 2024 and unaudited financial statements for the six months ended June 30, 2025. Exhibit 99.2 provides an unaudited pro forma condensed balance sheet as of June 30, 2025 and unaudited pro forma condensed statements of operations for the year ended December 31, 2024 and the six months ended June 30, 2025. The amendment does not otherwise modify or update the original report.
Tenon Medical, Inc. reported an unregistered issuance of 866,642 restricted stock units (RSUs) to its directors and officers under the company’s 2022 Equity Incentive Plan.
The RSUs vest in two equal tranches, with 50% on January 1, 2026 and 50% on July 31, 2026, and each RSU will convert into one share of common stock upon vesting. The issuance was made in reliance on Section 4(a)(2) of the Securities Act as a private offering.
Tenon Medical (TNON) reported a director equity award. Director Stephen Hochschuler received 21,464 restricted stock units (RSUs) on 10/13/2025 (Form 4, code A). Each RSU represents one share of common stock.
The grant vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The RSUs were reported at a price of $0 and are held directly.
Tenon Medical (TNON) filed a Form 4 reporting an equity award to a director. On 10/13/2025, the reporting person acquired 21,464 restricted stock units (RSUs), each representing the right to receive one share of common stock. The derivative security price is listed as $0.
According to the filing, vesting occurs in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. Following the transaction, 21,464 derivative securities are beneficially owned on a direct basis.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
